Rapid Skeletal Muscle Loss in Cirrhosis: Predictors, Outcomes, and Implications for Clinical Management

Highlight

• Median annual skeletal muscle loss in patients with cirrhosis awaiting liver transplantation is approximately 1.6%.

• Rapid muscle loss (RML), defined as the worst quartile of muscle loss (< -7.4% per year), predicts significantly higher waitlist mortality independent of MELD-Na score.

• Ascites and higher MELD-Na scores independently associate with increased risk of RML.

• Understanding the rate of muscle loss and its predictors informs prognostication and potential interventions targeting sarcopenia in cirrhosis.

Study Background

Skeletal muscle depletion, or sarcopenia, is a common and serious complication in patients with cirrhosis. It is associated with increased morbidity, poorer quality of life, and mortality. Since skeletal muscle mass is a modifiable factor, it represents a promising therapeutic target. However, despite known associations, the natural trajectory of muscle loss over time in cirrhosis patients—especially those awaiting liver transplantation—has not been well characterized. Knowledge of the rate of muscle mass decline and its clinical predictors could enhance risk stratification and guide intervention timing.

Study Design

This was a longitudinal cohort study conducted at a tertiary care center enrolling 364 ambulatory adult patients with cirrhosis listed for liver transplantation. Inclusion required patients to have undergone at least two abdominal computed tomography (CT) scans between February 2015 and January 2021, enabling quantification of skeletal muscle mass over time. Skeletal muscle index (SMI) was assessed at the third lumbar vertebra (L3) level, then normalized for patient height to provide an objective surrogate marker of muscle mass.

The primary endpoint was waitlist mortality, defined as death or delisting due to becoming too ill for transplantation. Annual percentage change in SMI (ΔSMI/year%) was calculated, with rapid muscle loss (RML) defined as the worst quartile of muscle loss (< -7.4% per year). Clinical predictors including ascites presence and MELD-Na scores were evaluated for association with RML and subsequent mortality risk.

Key Findings

The median age of patients was 62 years; 68% were male with a median MELD-Na score of 12. The median annual SMI change was -1.6%, indicating a gradual decline in muscle mass generally. However, 25% of patients demonstrated rapid muscle loss (< -7.4% per year), classified as RML.

Multivariate analysis identified two key independent predictors of RML: presence of ascites (OR 1.77; 95% CI 1.00–3.12) and higher MELD-Na scores (OR 1.06 per point; 95% CI 1.00–1.13). Thus, patients with more advanced liver disease and fluid accumulation were more likely to experience severe muscle wasting.

Most notably, RML patients experienced markedly increased waitlist mortality compared to those without RML—32% versus 10% at 12 months and 75% versus 27% at 24 months (log-rank p<0.001). Adjusted Cox proportional hazards models confirmed that RML independently predicted waitlist mortality with hazard ratios ranging from 3.43 to 3.52 after controlling for MELD-Na and other covariates.

These data underscore that muscle loss is a progressive and prognostically significant complication in cirrhosis, going beyond traditional liver severity scores. The findings highlight the importance of monitoring muscle status—through serial imaging or surrogate biomarkers—to identify high-risk patients.

Expert Commentary

This study by Yang et al. provides compelling evidence that rapid skeletal muscle loss serves as an independent and strong predictor of mortality among cirrhotic patients awaiting liver transplantation. It aligns with prior literature emphasizing the detrimental impact of sarcopenia on cirrhotic outcomes but extends our understanding by quantifying the rate of muscle change over time and linking it to clinical endpoints.

From a pathophysiological perspective, sarcopenia in cirrhosis is multifactorial, involving hyperammonemia, systemic inflammation, hormonal imbalances, malnutrition, and physical inactivity. Ascites contributes further by exacerbating metabolic derangements and reducing physical mobility. MELD-Na reflects overall liver disease severity and systemic dysfunction, making it intuitive that higher scores relate to greater muscle catabolism.

Clinically, integration of muscle mass assessment into routine cirrhosis management could facilitate earlier identification of patients at risk of poor outcomes. Interventions such as nutritional supplementation, resistance exercise, and emerging anabolic agents may then be targeted more effectively, although high-quality intervention trials remain limited.

Limitations include the single-center design and reliance on CT imaging, which may limit broad applicability. Future studies should explore muscle loss trajectories in diverse populations and validate non-invasive muscle quantification methods. Incorporation of functional muscle assessments and quality of life measures could enrich the clinical relevance further.

Conclusion

This study establishes that skeletal muscle loss occurs progressively in cirrhosis patients awaiting transplantation, with rapid muscle loss affecting a substantial minority. RML independently predicts waitlist mortality beyond MELD-Na, emphasizing the critical prognostic role of sarcopenia. Ascites and liver disease severity are key clinical predictors of muscle decline.

These insights provide a benchmark for future interventional trials targeting sarcopenia and suggest muscle mass monitoring should be integrated into the clinical evaluation of cirrhosis patients. Ultimately, combating sarcopenia has potential to improve survival and transplant candidacy in this vulnerable population.

Funding and Clinical Trials

The article does not specify funding sources or clinical trial registration. Future dedicated trials and registries targeting sarcopenia in cirrhosis are encouraged to build on these cohort findings.

References

1. Yang TC, Ha NB, Fan B, et al. Rate and clinical predictors of skeletal muscle loss in patients with cirrhosis. Gut. 2026 Jul 30. PMID: 42532672.
2. Montano-Loza AJ et al. Sarcopenia and mortality in cirrhosis: A systematic review and meta-analysis. J Hepatol. 2016;64(6):1224-1230.
3. Kaido T, Ogawa K, Fujimoto Y, et al. Impact of sarcopenia on outcomes after liver transplantation. Liver Transpl. 2013;19(11):1239-1246.
4. Sinclair M, Gow PJ, Grossmann M, Angus PW. Review article: Sarcopenia in cirrhosis—aetiology, implications and potential therapeutic interventions. Aliment Pharmacol Ther. 2016;43(7):765-777.